Biochemical and In Vivo Properties of High Purity Factor IX Concentrates

Summary

The purified factor IX concentrates Nanotiv (Kabi Pharmacia), Immunine (Immuno), Factor IX VHP (Bio-transfusion), Alphanine (Alpha) and Mononine (Armour) have been studied in vitro and compared with the prothrombin complex concentrates (PCCs) Preconativ (Kabi Pharmacia) and Prothromplex TIM4 (Immuno). The measured values for factor IX coagulant activity (IX: C) were in good agreement with the manufacturer’s label values. In contrast to the PCCs, most of the purified concentrates were virtually devoid of other vitamin K-dependent coagulation factors, the inhibitors protein C and S as well as fibrinogen, fibronectin and immunoglobulins. Indicators of thrombin generation, namely prothrombin fragments 1 and 2 (F 1 + 2) and thrombin-antithrombin complex (TAT), were present in varying amounts in all preparations. The specific activity in the purified concentrates exceeded that in the PCCs by a factor of 50-100. Some differences in purity were found between the purified concentrates.

In vivo, Nanotiv was compared with Preconativ and Immunine with Prothromplex TIM4 in crossover studies in patients with severe hemophilia B, and Mononine was tested in a single drug study. Most of the preparations yielded postinfusion increases in TAT, but not in FI + 2. Pharmacokinetic variables were analyzed with non-linear curve-fitting combined with model-independent methods. In retrospective comparisons, there were no apparent differences between Nanotiv, Preconativ and Mononine, whereas in vivo recovery seemed lower and the apparent clearance higher for Immunine and Prothromplex. Purified factor IX concentrates were successfully used as cover for surgery or in immune tolerance induction.

• References

• 1 Hultin MB, Dattwyler RJ, Lipton RA. Controlled prospective study of factor IX concenctrate therapy and immunodeficiency. Am J Hematol 1989; 31: 71-72
• 2 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28: 3-5
• 3 White II GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: Potentially thrombogenic material and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-70
• 4 Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-837
• 5 Giles AR, Nesheim ME, Hoogendorn H, Tracy PB, Mann KG. The coagulant active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401-407
• 6 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Botasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-2545
• 7 Giddings JC. Hereditary coagulation disorders: laboratory techniques. In: Blood Coagulation and Haemostasis. Thomson JM. ed. Churchill Livingstone: 1980. pp 117-57
• 8 Wallmark A, Ljung R, Nilsson IM, Holmberg L, Hedner U, Lindvall M, Sjögren H-O. Polymorphism of normal factor IX detected by mouse monoclonal antibodies. Proc Natl Acad Sci 1985; 82: 3839-3843
• 9 Lethagen S, Östergaard H, Nilsson IM. Clinical application of the chromogenic assay of factor VIII in haemophilia A, and different variants of von Willebrand’s disease. Scand J Haematol 1987; 37: 448-453
• 10 Ingerslev J. A sensitive ELISA for von Willebrand factor (vWF: Ag). Scand J Clin Lab Invest 1987; 47: 143-149
• 11 Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and s and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437-443
• 12 Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci 1986; 83: 9169-9173
• 13 Feldschuh J, Enson Y. Prediction of the normal blood volume: relation of blood volume to body habitus. Circulation 1977; 56: 605-12
• 14 Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 385-395
• 15 Gibaldi M, Perrier D. Pharmacokinetics. 2nd. ed. NewYork, NY: MarcelDekker, Inc; 1982
• 16 Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 1974; 2: 123-148
• 17 Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL. Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. Am J Hematol 1992; 40: 210-215
• 18 Smith KJ, Thompson AR. Labeled factor IX kinetics in patients with hemophilia B. Blood 1981; 58: 625-629
• 19 Longo G, Cinotti S, Filimberti E, Giustarini G, Messori A, Morfini M, Rossi FerriniP. Single-dose pharmacokinetics of factor IX evaluated by model–independent methods. Eur J Haematol 1987; 39: 426-433
• 20 Köhler M, Seifried E, Hellstem P, Pindur G, Miyashita C, Mörsdorf S, Fasco F, Wenzel E. In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. Blut 1988; 57: 341-345
• 21 Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-386
• 22 Hoag MS, Johnson FF, Robinson JA, Aggeler PM. Treatment of hemophilia B with a new clotting-factor concentrate. N Eng J Med 1969; 280: 581-586
• 23 Zauber NP, Levin J. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine 1977; 56: 213-224
• 24 Kim HC, McMillan CW, White GC, Bergman GE, Saidi P. Clinical experience of a new monoclonal antibody purified factor IX: Halflife, recovery, and safety in patients with hemophilia B. Semin Hematol 1990; 27 (Suppl. 02) 30-35
• 25 Noe DA, Bell WR, Ness PM, Levin J. Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. Blood 1986; 67: 969-972
• 26 Morfini M, Longo G, Cinotti S, Filimberti E, Messori A, Rafanelli D, Mannucci PM. Comparative single-dose pharmacokinetic study of Alphanine vs Profilnine. Thromb Haemostas 1991; 65: 1362 (abstract)
• 27 Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-575